Europe
Angelman Syndrome is a genetic disorder that mostly affects the nervous system.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 13, 2020.
The designation will provide for an expedited pathway for regulatory review of the preventative medication, which could come later this year.
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
BioNTech Chief Executive Officer Ugur Sahin predicts the company’s vaccine for COVID-19, which is it co-developing with Pfizer, could be ready for regulatory approval by the end of the year, with hundreds of millions of doses available for immediate distribution.
Even before a vaccine for the novel coronavirus has been completely developed, nations across the globe are jockeying for position to lay claim for the potential preventative medicine in something of a healthcare arms race.
A collective of pharmaceutical companies, including Pfizer, Merck, GlaxoSmithKline, Johnson & Johnson, has pledged financial support of approximately $1 billion to support the Antimicrobial Resistance Action Fund.
Forbion, a European life sciences venture capital firm, announced today that it had closed its Forbion Growth Opportunities Fund at $208 million.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.
PRESS RELEASES